Clinical Trial

CTS2190 Phase I /II Clinical Study in Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 23, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-17; most recent amendment 2024-08-21.
Trial Details
NCT Number NCT06224387
Lead Sponsor CytosinLab Therapeutics Co., Ltd.
Conditions Solid Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Triple-negative Breast Cancer
Enrollment 224 participants
Start Date 2023-06-26
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-23